CD274 and non-small cell lung carcinoma: KEYNOTE-024 provided the highest level of clinical evidence certifying that immunotherapy accompanied with PD-L1 diagnosis could bring nearly clinical cure outcome to advanced non-small cell lung cancer (NSCLC) (118).